Canaccord Genuity Morning Coffee on Pfizer (PFE): Woof!
Tweet Send to a FriendGet Alerts PFE Hot Sheet
Price: $28.78 +0.28%
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade PFE Now!
Canaccord Genuity Morning Coffee on Pfizer (NYSE: PFE): Woof!
Shares of Pfizer were up slightly after the drug maker said that it plans to take its animal health unit public rather than sell it to a potential buyer to avoid hefty taxes. Pfizer said that preparations were under way for a public offering of a minority stake in its animal health business, which will be called Zoetis. The animal-health unit reported revenue of about $4.2 billion in 2011 selling medicines, diagnostics, vaccines and other products to veterinarians and pet owners. Pfizer said it plans to use proceeds from divestitures to repurchase shares, which could help bolster per-share earnings in coming years as the company is pressured by the recent loss of market exclusivity for blockbuster cholesterol drug Lipitor. The company didn't specify what percentage stake it plans to sell in the IPO, or how much it expects to receive in proceeds, but will provide more details when it releases its second-quarter earnings report this summer. Just six weeks ago, Pfizer agreed to sell its infant nutrition business for $11.85 billion to Nestle SA. While in the third quarter of 2011, Pfizer sold its Capsugel capsule-making business to private equity firm Kohlberg Kravis Robert & Co. (NYSE: KKR) for $2.38 billion in cash. The moves are part of a major corporate makeover as the company tries to shed weight to focus more intently on its core pharmaceuticals business.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of Pfizer were up slightly after the drug maker said that it plans to take its animal health unit public rather than sell it to a potential buyer to avoid hefty taxes. Pfizer said that preparations were under way for a public offering of a minority stake in its animal health business, which will be called Zoetis. The animal-health unit reported revenue of about $4.2 billion in 2011 selling medicines, diagnostics, vaccines and other products to veterinarians and pet owners. Pfizer said it plans to use proceeds from divestitures to repurchase shares, which could help bolster per-share earnings in coming years as the company is pressured by the recent loss of market exclusivity for blockbuster cholesterol drug Lipitor. The company didn't specify what percentage stake it plans to sell in the IPO, or how much it expects to receive in proceeds, but will provide more details when it releases its second-quarter earnings report this summer. Just six weeks ago, Pfizer agreed to sell its infant nutrition business for $11.85 billion to Nestle SA. While in the third quarter of 2011, Pfizer sold its Capsugel capsule-making business to private equity firm Kohlberg Kravis Robert & Co. (NYSE: KKR) for $2.38 billion in cash. The moves are part of a major corporate makeover as the company tries to shed weight to focus more intently on its core pharmaceuticals business.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Goldman Sachs Upgrades Meritor (MTOR) to Buy
- UPDATE: Intuit, Inc. (INTU) Tops Q3 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Analyst Comments, IPOsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
